Currently Recruiting Trials – Low Grade Glioma

Clinical trials for adult grade II glioma patients are few and far between. A search on the clinicaltrials.gov database turns up only a few results. In this section I’ll be covering trials for adult WHO grade II astrocytoma, oligodendroglioma, and oligoastrocytoma.

Page last updated: January 24, 2017

New Trials (Added here in the last month)

Added January 24, 2017
Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG). University of California San Francisco. Estimated primary completion date: January 2018.
NCT02924038

Newly Diagnosed

Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG). University of California San Francisco. Estimated primary completion date: January 2018.
NCT02924038

Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines [GBM6-AD lysate protein and poly-ICLC] in Adult Patients With WHO Grade II Glioma. University of California San Francisco. Estimated primary completion date: September 2018. For newly diagnosed or recurrent grade II glioma (astrocytoma, oligodendroglioma, oligoastrocytoma).
NCT02549833

Proton therapy

Note: these trials are for newly diagnosed or recurrent patients who haven’t had prior radiation therapy.

Proton Radiation Therapy for Low Grade and Favorable Grade 3 Gliomas. Phase II. The “favorable” descriptor in the title refers to grade III patients with either IDH1 mutation or codeletion of chromosomes 1p and 19q. This is a single-centre study being conducted at the Massachusetts General Hospital in Boston. Patients receive a total of 54 Gy of radiation over a course of six weeks. Estimated enrollment is 40 patients and estimated primary completion date is May 2017.
NCT01358058

A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation. Boston, MA. Estimated primary completion date: January 2020. Ages 1-25.
NCT01288235

Recurrences

Immune therapies

Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG). University of California San Francisco. Estimated primary completion date: January 2018.
NCT02924038

Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines [GBM6-AD lysate protein and poly-ICLC] in Adult Patients With WHO Grade II Glioma. University of California San Francisco. Estimated primary completion date: September 2018. For newly diagnosed or recurrent grade II glioma (astrocytoma, oligodendroglioma, oligoastrocytoma).
NCT02549833

A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas. Pittsburgh PA. Estimated primary completion date: September 2016. High-risk in this trial is defined as any of the following: age 40 or over; imcomplete resection; preoperative tumor diameter over 4 cm.
NCT01678352

RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine. Duke University, Durham, North Carolina. Estimated primary completion date: May 2017.
NCT02193347

Targeting mutant IDH1 or IDH2

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation. Los Angeles CA, Nashville TN, Houston TX. Estimated primary completion date: September 2018.
NCT02481154
Agios news release

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations. Recruiting in Houston TX, Melbourne Australia, Toronto Canada, and Singapore. Not yet recruiting in Boston MA, New York NY, Parkville Australia, Leuven Belgium, Heidelberg and Jena Germany, Amsterdam and Rotterdam Netherlands, and Barcelona Spain. Estimated primary completion date: November 2017.
NCT02381886